# Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection

> **NCT03820258** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 21 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** SOF/VEL/VOX

## Key facts

- **NCT ID:** NCT03820258
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-28
- **Primary completion:** 2019-12-04
- **Final completion:** 2020-02-19
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** SOF/VEL/VOX will not be evaluated in younger age groups.
- **Last updated:** 2020-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03820258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03820258, "Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03820258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*